- |||||||||| Bimzelx (bimekizumab) / UCB
Review, Journal: Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. (Pubmed Central) - May 24, 2023
Despite numerous biologics are currently available for psoriasis, some patients may result resistant to other treatments, and/or experience psoriatic flares during or after treatment withdrawal. In this scenario, bimekizumab may represent an additional valuable alternative for patients with moderate to severe forms of psoriasis.
- |||||||||| Review, Journal: New molecules for atopic dermatitis treatment beyond biological therapy. (Pubmed Central) - May 19, 2023
In this scenario, bimekizumab may represent an additional valuable alternative for patients with moderate to severe forms of psoriasis. These new drugs (systemic and topical) are needed to increase the success of AD treatment, particularly for patients who do not or no longer respond to treatment.
- |||||||||| TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF 101 PATIENTS OF CLINICAL PRACTICE () - May 19, 2023 - Abstract #EULAR2023EULAR_4377;
However, this study is limited by the small number of cases and its retrospective design. Background Upadacitinib (UPA) is an inhibitor of JAK kinases recently approved by EMA for the treatment of psoriatic arthritis (PsA) in Europe (January 2021) [1] UPA has shown efficacy in refractory patients to anti-TNF [2] Objectives A ) to assess efficacy and safety of UPA in the first cases in Spain in clinical practice...Pattern joint involvement was: peripheral (n=61) axial (8) and mixed (32) During the PsA evolution patients presented enthesitis (38.6%) nail involvement (22%) and dactylitis (25.7%) Prior to UPA most patients (71.3%) received oral prednisone or equivalent (mean maximum dose 12.04
- |||||||||| Review, Journal: Expert Consensus on the Systemic Treatment of Atopic Dermatitis in Special Populations. (Pubmed Central) - May 15, 2023
A modified Delphi process was used to arrive at a set of final consensus statements related to the systemic treatment of AD in these specific patient populations. To provide practical guidance on the choice of systemic therapy for atopic dermatitis in these six topics of clinical interest, 25 expert consensus statements and a summary of the supporting data are presented herein.
- |||||||||| Review, Journal: Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence. (Pubmed Central) - May 14, 2023
Physicians who treat patients with AD with Jak inhibitors and biologics need to understand the current evidence and choose the best treatment for individual patients. In this review, we discuss how integrating knowledge of the mechanisms of action of Jak inhibitors and biologics, the potential significant adverse events of these drugs, and the age and comorbidities of the patient can help achieve optimal clinical benefit for patients with moderate-to-severe AD refractory to topical agents.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Application of low-level laser with 1064nm Q-switched Nd: YAG laser may ameliorate atopic dermatitis (Poster Zone A) - May 13, 2023 - Abstract #EAACI2023EAACI_2235;
Method Experimental AD mouse model triggered by topical application of MC903 was employed...Conclusion 1064-nm QS laser with the energy under LLLT ameliorates AD skin lesions and itch by inhibiting Th2 responses. 1064-nm QS laser can be considered a potential therapeutic choice for AD.
- |||||||||| Review, Journal: "The Evolving Landscape of Immunotherapy for the Treatment of Allergic Conditions". (Pubmed Central) - May 12, 2023
As biologics become more targeted, fewer off-target effects are seen improving tolerability for patients as well as expanded options for treatment of these conditions. This review discusses monoclonal antibody therapies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, tralokinumab) including their safety and use in asthma, chronic urticaria, atopic dermatitis, and eosinophilic esophagitis.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
IL-13 inhibition used for atopic diseases is associated with risk of psoriatic arthritis (Poster View) - May 10, 2023 - Abstract #EULAR2023EULAR_2922;
Clinicians assessing adverse events after dupilumab initiation should be aware of incident PsA and related features. This study demonstrates the value of genetic instrumental variable analyses in evaluating rare adverse events in the study of drug safety.
- |||||||||| Innohep (tinzaparin) / LEO Pharma
Trial completion date, Trial primary completion date: TILE: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome (clinicaltrials.gov) - May 10, 2023
P4, N=60, Recruiting,
This study demonstrates the value of genetic instrumental variable analyses in evaluating rare adverse events in the study of drug safety. Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- |||||||||| orismilast oral (LEO 32731) / UNION Therap
Trial completion, Trial initiation date: A Study of IBI353 (Orismilast) in Chinese Healthy Adults (clinicaltrials.gov) - May 6, 2023
P1, N=20, Completed,
Recruiting --> Active, not recruiting Not yet recruiting --> Completed | Initiation date: Sep 2022 --> Nov 2022
- |||||||||| Innohep (tinzaparin) / LEO Pharma
Journal: Recurrent, life-threatening PE in the setting of popliteal vein aneurysm in pregnancy: a case report. (Pubmed Central) - May 6, 2023
Ultimately, patients with PVA and PE should undergo surgical resection to reduce the risk of recurrence and long-term complications. The ideal duration of post-operative anticoagulation remains unclear, and should likely be decided on based on risks, benefits, values, and shared decision making with the patient and their care provider.
- |||||||||| Review, Journal: How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? (Pubmed Central) - May 2, 2023
We have now reached the point of creating new strategies and AD treatment goals by increasing the amount of new information concerning the efficacy and safety of new drugs. This article has reviewed the novel treatment options for AD in the light of the heterogeneity of this disease and proposes a broader vision on the strategy of personalized treatment of AD.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results. (Pubmed Central) - May 1, 2023
Tralokinumab was found to be effective in most patients in this cohort with difficult-to-treat, severe AD from daily practice. Interestingly, tralokinumab was also found to be effective in 50% of patients who had previously experienced insufficient response or adverse events with dupilumab treatment.
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Immediate hypersensitivity reaction to ixekizumab: a case report (Poster Zone C) - Apr 30, 2023 - Abstract #EAACI2023EAACI_1677;
Interestingly, tralokinumab was also found to be effective in 50% of patients who had previously experienced insufficient response or adverse events with dupilumab treatment. Case Report Biologic drugs are becoming the mainstay of treatment for many inflammatory and oncologic diseases.They are currently used for moderate-to-severe psoriasis, that is a chronic inflammatory disease with genetic predisposition and autoimmune pathogenic traits involving the skin, joints, or both.
- |||||||||| Reduction in topical corticosteroids prescribed post immunomodulatory systemic treatment initiation in moderate-to-severe atopic dermatitis: a retrospective real-world chart analysis (Poster Zone C) - Apr 30, 2023 - Abstract #EAACI2023EAACI_1146;
Method Patients receiving systemic treatment (dupilumab, tralokinumab, baricitinib, upadacitinib or abrocitinib) for AD as standard care in the Department of Dermatology of the University Hospital Jena were reviewed...TCS prescribed prior and post-systemic treatment were mainly methylprednisolone aceponate 0,1% (45.7% prior vs. 76.8% post), mometasone furoate 0,1% (27.6% prior vs. 17.9% post) and betamethasone valerate 0,1% (22.9% prior vs. 1.9% post), all potent TCS (group III) according to WHO...Due to retrospective study design, data was available for analysis only for a limited number of cases and primarily for subjects treated with dupilumab. Further prospective studies should be conducted to assess TCS sparing effect of immunomodulatory systemic treatments for AD.
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Effectiveness of brodalumab in (Level 3 - Room 331) - Apr 24, 2023 - Abstract #WCD2023WCD_2210;
Brodalumab proved to be effective and safe in the treatment of scalp, genital and palmoplantar regions. The data are in line if not superior with those currently reported in the literature for brodalumab and other biologics
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Diminished ?? T Cells during allergic skin inflammation is mediated by IL-4 signaling in keratinocytes (P411) (Exhibit Hall; Poster Board No. P411) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1033;
Our previous work identified a loss of DETC in Stat6VT mice and in MC903 induced skin inflammation mouse model that was dependent on IL-4...Together, these results identify an IL-4-dependent circuit that regulates DETCs in the skin by repressing IL-15 expression in keratinocytes. This provides further insights into the ability of IL-4 to promote the development of atopic lesions and impair wound healing.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
The roles of epidermal Blimp-1 in atopic dermatitis (P507) (Exhibit Hall; Poster Board No. P507) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_889;
Since K5-CreER+ Prdm1f/f (CKO) mice in Balb/c background exhibited AD-like symptoms, we wondered whether they are more susceptible to the disease progression in a murine AD model induced by MC903, a vitamin D3 analog enhancing TSLP production by keratinocytes...Indeed, both in vivo and in vitro deletion of Prdm1 in keratinocytes resulted in elevated levels of ERV transcripts. We are studying the contribution of elevated ERV transcripts in Blimp-1-reduction-mediated AD-like skin inflammation.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Lecture 6: Molecular insight of topical emollient on the development of atopic dermatitis and atopic march in a mice model: Q&A (Harmony, 44F Keio Plaza Hotel, Tokyo) - Apr 5, 2023 - Abstract #ISID2023ISID_1890;
Following induction of atopic dermatitis with topical calcipotriol (MC903) and ovalbumin (OVA), one group of mice was treated topically with a linoleic acid-ceramide-containing emollient, while mice without emollient treatment served as controls...In conclusion, Topical emollient not only reduces skin inflammation, but also mitigates systemic inflammation by decreasing TSLP and IgE levels. Moreover, topical emollient reduces chemokine production, and basophil infiltration and activation in the lung, providing a molecular basis for blocking the atopic march.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Lecture 6: Molecular insight of topical emollient on the development of atopic dermatitis and atopic march in a mice model: Presentation (Harmony, 44F Keio Plaza Hotel, Tokyo) - Apr 5, 2023 - Abstract #ISID2023ISID_1889;
Following induction of atopic dermatitis with topical calcipotriol (MC903) and ovalbumin (OVA), one group of mice was treated topically with a linoleic acid-ceramide-containing emollient, while mice without emollient treatment served as controls...In conclusion, Topical emollient not only reduces skin inflammation, but also mitigates systemic inflammation by decreasing TSLP and IgE levels. Moreover, topical emollient reduces chemokine production, and basophil infiltration and activation in the lung, providing a molecular basis for blocking the atopic march.
- |||||||||| Enrollment closed, Enrollment change: ACTIV-4: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (clinicaltrials.gov) - Apr 5, 2023
P4, N=880, Active, not recruiting,
Moreover, topical emollient reduces chemokine production, and basophil infiltration and activation in the lung, providing a molecular basis for blocking the atopic march. Recruiting --> Active, not recruiting | N=3000 --> 880
- |||||||||| Stelara (ustekinumab) / J&J, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Biomarker, Clinical, Retrospective data, Review, Clinical Trial,Phase I, Journal, Benefit-risk assessment: Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis. (Pubmed Central) - Apr 4, 2023
Recruiting --> Active, not recruiting | N=3000 --> 880 This case study demonstrates how to implement the ISPOR Task Force's good practice recommendations on qBRA.
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Deep Analysis of Skin Molecular Heterogeneities and their Implications on the Precise Treatment of Patients with Psoriasis (Poster View) - Apr 2, 2023 - Abstract #EULAR2023EULAR_2060;
inhibitors (etanercept) and IL-17RA inhibitors (brodalumab) but not MTX and IL-12/23 inhibitors. Conclusion Deep stratification based on skin heterogeneities was employed to categorize patients with psoriasis into three subtypes with distinct molecular and cellular signatures, which determined the clinical responses of different conventional therapies.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Safety of tralokinumab in atopic dermatitis. (Pubmed Central) - Mar 31, 2023
Conclusion Deep stratification based on skin heterogeneities was employed to categorize patients with psoriasis into three subtypes with distinct molecular and cellular signatures, which determined the clinical responses of different conventional therapies. No abstract available
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Preclinical, Journal: Mouse Models for Atopic Dermatitis. (Pubmed Central) - Mar 28, 2023
This article is a U.S. Government work and is in the public domain in the USA. Basic Protocol 1: Application of MC903 and gross phenotype assessment Basic Protocol 2: Processing skin for flow cytometry analysis Support Protocol: Skin immune cell surface staining and flow cytometry analysis Basic Protocol 3: Harvesting skin for histologic analysis Basic Protocol 4: Immunofluorescence staining to identify immune cell infiltrates.
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: Ein m (Pubmed Central) - Mar 24, 2023
This review provides an in-depth, practical discussion on use of these biologics and JAK inhibitors that are approved or have completed phase 3 clinical trials in pediatric patients and adults, comparing the groups of medications based on available efficacy and safety data. No abstract available
|
